Response and Resistance to Menin Inhibitor in UBTF-Tandem Duplication AML

N Engl J Med. 2024 Jun 27;390(24):2323-2325. doi: 10.1056/NEJMc2404110.
No abstract available

Publication types

  • Letter
  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzamides / therapeutic use
  • Drug Resistance, Neoplasm* / drug effects
  • Drug Resistance, Neoplasm* / genetics
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics
  • Male
  • Mutation / drug effects
  • Mutation / genetics
  • Pol1 Transcription Initiation Complex Proteins
  • Proto-Oncogene Proteins* / drug effects
  • Proto-Oncogene Proteins* / genetics
  • Recurrence
  • Spiro Compounds / therapeutic use
  • Transcription Factors / genetics
  • Treatment Outcome
  • Young Adult

Substances

  • Proto-Oncogene Proteins
  • Transcription Factors
  • Benzamides
  • Spiro Compounds
  • MEN1 protein, human
  • revumenib
  • transcription factor UBF
  • Pol1 Transcription Initiation Complex Proteins